Shanghai Junshi Biosciences has unveiled promising early clinical results from multiple studies at the 2026 AACR Annual Meeting, focusing on their innovative pipeline of bispecific antibodies and antibody-drug conjugates (ADCs). Key assets include JS212, a recombinant humanized anti-EGFR/HER3 bispecific ADC, and JS207, an anti-PD-1/VEGF bispecific antibody. These therapies are positioned as pivotal components of Junshi’s Immuno-Oncology 2.0 (IO 2.0) strategy, showcasing significant potential in enhancing treatment efficacy, especially in resistant cancer populations.

The clinical data presented highlights the objective response rates (ORR) of 45.5% for JS207 combined with JS007 in advanced hepatocellular carcinoma (HCC) and an impressive 71.0% for JS207 in combination with chemotherapy for metastatic colorectal cancer (mCRC). Both combinations demonstrated favorable tolerability profiles, with no dose-limiting toxicities reported. The disease control rates (DCR) were also notable, reaching 86.4% for HCC and 96.8% for mCRC, indicating strong therapeutic potential in these challenging malignancies. Furthermore, JS212’s first-in-human data revealed an ORR of up to 50% in specific solid tumor types, underscoring its promising efficacy across various cancer indications.

These findings have significant implications for the field, particularly in shifting the paradigm toward dual-target immunotherapy strategies that combine immune checkpoint inhibition with traditional chemotherapy. The encouraging results support the continued exploration of these bispecific therapies in broader clinical settings, potentially accelerating drug development timelines and enhancing treatment options for patients with advanced malignancies. As Junshi progresses with proof-of-concept studies, the integration of these innovative therapies could redefine standard care approaches in oncology.

Source: globenewswire.com